Best Life Sciences Companies in Austria
The 220 best Life Sciences companies in Austria in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nabriva.
Austria's Life Sciences sector has 220 companies tracked, $910M in disclosed funding, and no unicorns yet — which tells you something real about where the opportunity sits. Hookipa Pharma leads the pack at $134M raised, with Innovacell Biotechnologie ($17M) and SteadySense ($7M) rounding out a mid-tier that's quietly building. The global market is moving fast: life sciences is a $167.8B industry expanding at a 10.2% CAGR, driven by aging populations and sustained institutional funding. That tailwind is real, and Austria's startups are positioned to catch it.
So what's the actual momentum signal? Across health and life sciences apps, median install growth is running at roughly +43% year-over-year, which I'd call a telling proxy for where end-user demand is heading. And globally, the IPO pipeline is moving too — Sai Life Sciences' fresh-issue IPO push signals that capital markets still have appetite for the sector. Investors like FFG, Austria Wirtschaftsservice, and INiTS are the most active backers here domestically, keeping early-stage deal flow alive even without a breakout unicorn. If you're mapping the Austrian ecosystem, this is the list to start with.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Austria
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nabriva Developer of pleuromutilin class of antibiotics for MDR infections | $193M | 89 mo ago | Public | 39 | — | 3 signals ▼40% Leadership | — | — |
| 2 | HOOKIPA Pharma Developer of immunotherapies for the treatment of infectious diseases and cancer | $134M | 30 mo ago | Public | 132 | — | 6 signals ▼82% Acquisition | — | — |
| 3 | AFFiRiS Developer of therapeutics for neurodegenerative diseases | $83M | 109 mo ago | Series B | 10 | Frank Mattner Founder | — | 459 patents Peptide-based therapeutic vaccines targeting neurodegenerative and hypercholesterolemia diseases | — |
| 4 | Themis Bioscience Prophylactic vaccines for infectious diseases | $83M | 81 mo ago | Acqui-Hired | 40 | — | — | 60 patents Recombinant viral vaccine vectors and co‑stimulatory ectodomain proteins for immunomodulation | — |
| 5 | Intercell Developer of vaccines for infectious diseases (merged with Vivalis {France} to form Valneva in 2012) | $79M | 183 mo ago | Acquired | — | Arunabh Varma Founder & CEO | — | 405 patents Vaccines and immunostimulatory oligodeoxynucleotide formulations targeting bacterial pathogens. | — |
| 6 | Igeneon Cancer Immunotherapy drug discovery company acquired by Aphton in 2004, deadpooled in 2006 | $60M | 268 mo ago | Deadpooled | — | — | — | 3 patents Nanoparticle-based vaccine delivery platforms combining antigens, adjuvants, and immunogenic structures. | — |
| 7 | Apeiron Biologics Developer of tumour targeting antibodies and small molecule immunotherapeutics for the treatment of cancer | $30M | 73 mo ago | Acquired | 14 | — | — | 232 patents Patents concentrated in health & consumer products | — |
| 8 | Ribbon Biolabs Developer of a technology platform for the synthesis of long DNA molecules | $20M | 52 mo ago | Series A | 38 | Harold De Vladar Founder and Advisory Board Member | — | 30 patents Enzymatic synthesis and assembly of custom nucleic acid polymers. | 3 launchs |
| 9 | Innovacell Biotechnologie Developer of cell-treatment for the treatment of incontinence | $17M | 18 mo ago | Series D | 22 | Ekkehart Steinhuber Co-Founder & CEO | — | 72 patents Isolation and preparation of autologous muscle-derived cells for regenerative cell therapies | — |
| 10 | Platomics Marketplace provider for the genomic test-based personalized medicines | $16M | 56 mo ago | Series A | 48 | Kriegner Albert CEO | — | — | 1 launch |
| 11 | YGION Developer of immunotherapies for the treatment of cancer | $16M | 24 mo ago | Series A | — | Alexander Seitz Co-Founder | — | — | 1 job opening |
| 12 | OncoOne Developer of drug for treating patients with solid tumors | $14M | 75 mo ago | Series A | 16 | Randolf Kerschbaumer Co-Founder & CEO | — | — | 1 partnership |
| 13 | OrthoPulse Light energy to correct tooth misalignment | $14M | 85 mo ago | Series A | — | Peter Brawn Founder | — | — | — |
| 14 | Flinn AI-enabled solution for manufacturers to automate compliance processes | $11M | 3 mo ago | Series A | — | Hasib Samad Co-Founder - Tech | 3 signals ▼25% Funding | — | — |
| 15 | Sarcura Developer of cell therapy solutions for multiple therapeutic areas | $10M | 36 mo ago | Seed | 25 | Erwin Gorjup Chief Scientific Officer & Co-Founder | — | — | — |
| 16 | g.tec Provider of high-performance brain-computer interfaces and neurotechnologies for invasive and non-invasive… | $10M | 53 mo ago | Funding Raised | 116 | Christoph Guger Founder & CEO | — | — | 1 launch |
| 17 | invIOs Developer of immunotherapies for the treatment of cancer | $9M | 20 mo ago | Series A | — | Peter Llewellyn-Davies CEO | — | 11 patents Engineered immune cell production and small‑molecule immunomodulators for therapeutic use | — |
| 18 | Biocrates Developer of targeted metabolic phenotyping solutions | $8M | 81 mo ago | Acquired | 63 | — | — | — | — |
| 19 | kiweno Provider of clinical labs for food and histamine intolerance diagnosis tests | $8M | 122 mo ago | Public | 24 | — | — | — | — |
| 20 | SteadySense Provider of remote monitoring medical devices | $7M | 7 mo ago | Series B | 12 | — | — | 13 patents Wearable medical sensor patches with protective layers for biophysical monitoring | 2 launchs |
| 21 | HeartBeat Developer of stem-cell derived organoid models for cardiac drug discovery | $7M | 31 mo ago | Seed | 14 | Michael Krebs Founder & CEO | — | — | — |
| 22 | Marinomed Developer of drugs for immunology, allergy and infectious diseases | $6M | 56 mo ago | Public | 44 | Eva Prieschl-Grassauer Co-Founder | 15 signals ▼53% Capital raise · Earnings · Funding | — | 1 launch · 1 partnership · 1 expansion |
| 23 | Allcyte Developer of drugs for the treatment of cancer patients | $6M | 62 mo ago | Acquired | 30 | — | — | — | — |
| 24 | EveliQure Biotechnologies Developing a vaccine against Diarrhea using a proprietary technology platform | $6M | 81 mo ago | Funding Raised | 7 | Gabor Somogyi CEO | — | 35 patents High‑dose Shigella vaccine formulation and delivery technologies | — |
| 25 | 4a Medicom Products for the measurement of blood glucose | $5M | 188 mo ago | Deadpooled | — | Reinhard Hafellner Founder | — | 10 patents Integrated disposable point‑of‑care blood testing devices with capillary fluid handling | — |
| 26 | mySugr Gamification apps for diabetes management and therapy | $5M | 135 mo ago | Acquired | 130 | — | — | 27 patents Predictive analytics and risk assessment for blood glucose control in insulin therapy | — |
| 27 | Celeris Therapeutics Developer of an AI-driven degrader platform for drug discovery | $4M | 52 mo ago | Seed | 17 | Christopher Trummer Co-Founder & CEO | — | — | — |
| 28 | ViraTherapeutics Developer of oncolytic virus-based cancer therapeutics | $4M | 131 mo ago | Acquired | 19 | — | — | 37 patents Recombinant rhabdovirus vectors delivering CCL21 cytokine for cancer immunotherapy | — |
| 29 | Anagnostics In-vitro-diagnostics for sepsis | $4M | 207 mo ago | Acqui-Hired | 2 | Bernhard Ronacher Co-Founder & CSO | — | — | — |
| 30 | Graph Therapeutics Provider of AI-based precision immunology technology to develop targeted therapies and biomarkers for… | $3M | 17 mo ago | Seed | — | Berend Snijder Co-Founder | — | — | 2 job openings |
| 31 | Zytoprotec Develops cytoprotective therapies for the treatment of end-stage renal disease (ESRD) and other diseases | $3M | 89 mo ago | Series A | 10 | Christoph Aufricht Co-Founder | — | 34 patents Formulating protective amino‑acid and GSK‑3 inhibitor additives for peritoneal dialysis fluids. | — |
| 32 | Sealife Pharma Marine biotechnology company focused on developing antibiotics derived from marine fungi | $3M | 126 mo ago | Seed | — | Andreas Krems ex-Co-Founder | — | 76 patents Synthesis and application of bioactive polyguanidine polymers for pharmaceutical therapeutics | — |
| 33 | a:head bio Developer of therapeutics based on human cerebral organoids for brain disorders | $3M | 79 mo ago | Funding Raised | 15 | Oliver Szolar CEO | — | — | — |
| 34 | Valanx Biotech Develops tools for protein conjugation | $3M | 3 mo ago | Series A | 11 | Georg Altenbacher Co-Founder & CBO | — | 15 patents Bio-orthogonal click chemistry reagents for site-specific protein/peptide modification | — |
| 35 | Adhesion Therapeutics AI-enabled molecular glue degraders aimed at treating diseases | $3M | 47 mo ago | Funding Raised | — | Chris Tame Co-Founder & CSO | — | — | — |
| 36 | Ugichem Develops antisense drugs for inflammatory diseases | $3M | 156 mo ago | Deadpooled | — | Thomas Lindhorst ex-Co-Founder | — | 14 patents Synthesis of chiral phosphonate‑linked peptide nucleic acid monomers and oligomers | — |
| 37 | Biogena Manufacturer of micronutrient supplements, including vitamins, minerals, and plant substances | $2M | 22 mo ago | Seed | 138 | Albert Schmidbauer Founder & CEO | — | — | — |
| 38 | HELLO INSIDE Provider of continuous glucose monitoring sensors and related mobile application | $2M | 21 mo ago | Seed | 19 | Jürgen Furian Founder | — | — | — |
| 39 | Nagene Provider of gene synthesis solutions for customized DNA sequences | $2M | 26 mo ago | Seed | — | — | — | — | — |
| 40 | PhagoMed Company developing alternatives to antibiotics through their expertise in phage therapy | $2M | 83 mo ago | Acquired | 14 | Burkhard Wippermann Co-Founder | — | — | — |
| 41 | BIA Separations Develops monolithic chromatographic columns based on Convective Interaction Media Technology | $2M | 50 mo ago | Acquired | 2 | — | — | 17 patents Sulfated (SO3) chromatography media for virus purification in biopharmaceutical processing | — |
| 42 | Panoptes Pharma Small molecule drugs to treat eye diseases | $2M | 127 mo ago | Acqui-Hired | 5 | — | — | 44 patents Ophthalmic drug compounds and albumin-based eye-drop formulations for eye disease treatment | — |
| 43 | IONICON Real-time trace gas analyzers based on PTR-MS technology | $1M | 29 mo ago | Funding Raised | — | Lukas Mark CEO | — | — | 1 launch |
| 44 | Turn-Motion Developer of AI-powered platform for designing and manufacturing custom orthoses | $1M | 15 mo ago | Funding Raised | — | Chien-Hua Huang CTO & Co-founder | — | 2 patents Custom 3D‑printed orthopedic orthoses and their manufacturing processes | — |
| 45 | Ivary At-home diagnostic kits to assess the ovarian reserve | $1M | 111 mo ago | Deadpooled | — | Silvia Hecher Founder & CEO | — | — | — |
| 46 | Evercyte Cell lines, reagents and research services for pharma and cell therapies | $1M | 45 mo ago | Funding Raised | 7 | Otto Kanzler CEO & Co-Founder | — | 14 patents Targeted extracellular vesicle platforms for precision drug delivery | — |
| 47 | TissueGnostics Provider of instruments and software for digital pathology | $984K | 45 mo ago | Public | — | — | — | 16 patents Automated histological image analysis and leukocyte segmentation for diagnostic pathology | — |
| 48 | KiloBaser Developer of DNA and RNA synthesizer for research applications | $625K | 60 mo ago | Seed | 16 | Bernhard Tittelbach CoFounder / CTO | — | 8 patents Microfluidic lab‑on‑chip valves for automated oligonucleotide synthesis | 1 launch |
| 49 | imd Biotech Developer of diagnostic equipment for biomolecule detection and measurement | $431K | 25 mo ago | Seed | — | Peter Werzer Co-Founder | — | — | 2 partnerships · 2 awards |
| 50 | Akribes Biomedical Developing new drugs against chronic wounds using proprietary assays | $295K | 41 mo ago | Funding Raised | — | Barbara Wolff-Winiski Co-founder and CEO | — | 35 patents Topical therapies using selective glucocorticoid receptor modulators and PARP inhibitors for chronic skin wound healing | — |
Top 12 Life Sciences companies in Austria
#1
Series A · Vienna, Vienna · founded 2022$11.2Mraised▾
AI-enabled solution for manufacturers to automate compliance processes. It empowers medical device manufacturers to automate compliance processes to launch and operate high-quality products.
- Feb 2026Series A$20M
- Sep 2024Seed$6.7M
- Jul 2023Grant (prize money)$2.2M
- Dec 2022Seed$1.9M
#2
Series A · Graz, Styria · founded 2017 · 11 employees$2.7Mraised▾
VALANX is a biotech company that develops a site-specific protein conjugation platform to enable fast antibody-drug conjugates development as well as peptide conjugates and oriented immobilization for biosensors. They have patented reactive amino acid at defined sites and the site is encoded on the DNA level and is freely selectable.
- Mar 2026Series A$3.5M
- Nov 2023Series A$2.5M
- 2020Seed—
- Seed$253.4K
#3
Series B · Seiersberg, Styria · founded 2016 · 12 employees$6.7Mraised▾
SteadySense provides a remote monitoring platform for healthcare professionals and patients. The company develops a sensor-based device SteadyTemp in which a skin adhered patch will be attached to the patient's body and it will monitor the body temperature in real-time and give insights on mobile-based NFC (near field communication) enabled software platform.
- Oct 2025Series B—
- Mar 2019Series A$6.7M
#4
Series D · Innsbruck, Tyrol · founded 2000 · 22 employees$16.8Mraised▾
Innovacell Biotechnologie develops solutions that help to heal the fecal incontinence condition. Their technique involves the extraction of cells from bladder or sphincter muscles, which are then propagated in Innovacell's production facility. The propagated cells grow into and strengthen the existing sphincter. The firm has developed a proprietary ultrasound-guided instrument called the project which is used in the injection process. Their ICES13 product has completed phase II of clinical trials. The ICEF15 product for fecal incontinence has shown considerable promise in phase I and II of clinical trials.
- Dec 2024Series D$6.7M
- Apr 2012Series A$11M
- Sep 2010Series A$5.8M
- 2002Seed—
#5
Public · Vienna, Vienna · founded 2011 · 132 employees$133.7Mraised▾
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
- Dec 2023Post IPO$21.2M
- Feb 2019Series D$37.4M
- Dec 2017Series C$59.6M
- Oct 2016Grant (prize money)$4.6M
#6
Series A · Vienna, Vienna · founded 2019$9Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has a proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enabling rapid treatment of patients using their own cells. The lead candidate of the company is APN401 for the treatment of solid tumors. Other drug candidates include INV441 and INV501, an early-stage cell therapy approach to activate tumor-associated immune cells.
- Oct 2024Series A$9M
#7
Seed · Klosterneuburg, Lower Austria · founded 2024$3.1Mraised▾
Provider of AI-based precision immunology technology to develop targeted therapies and biomarkers for immune-driven diseases. It uses primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies & biomarkers for immune-driven diseases.
- Jan 2025Seed$3.1M
#8
Funding Raised · Vienna, Vienna · founded 2022$1.3Mraised▾
Developer of AI-powered platform for designing and manufacturing custom orthoses. It provides a system that integrates AI, automation, and fiber technology to produce precision-fit orthotics. The platform captures patient data via an application, uses AI to optimize the structural design, and automates the production process. This enables orthopedic technicians and medical supply stores to streamline orthotic care, reduce manual adjustments, and increase patient throughput. The company's technology facilitates the creation of lighter, biomechanically optimized orthoses that seamlessly integrate with joint systems, enhancing patient mobility and comfort.
- Mar 2025Grant (prize money)$1.3M
#9
Series A · Vienna, Vienna · founded 2022$16.3Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has YGNITE platform that combines next generation sequencing, bioinformatics and the proprietary CARGONAUT vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient.
- May 2024Series A$16.3M
#10
Seed · Vienna, Vienna · founded 2021 · 19 employees$1.8Mraised▾
Provider of continuous glucose monitoring sensors and related mobile application. The company offers tools for individuals to track blood sugar levels and understand metabolic responses. The application provides personalized recommendations based on user data, aiming to promote sustainable lifestyle changes. The offering includes educational programs designed to help users achieve health goals.
- Sep 2024Seed$1.8M
#11
Seed · Austria · founded 2004 · 138 employees$2.2Mraised▾
Manufacturer of micronutrient supplements, including vitamins, minerals, and plant substances. The company produces items such as vitamins, minerals, trace elements, amino acids, and intestinal bacteria supplements. It also offers products in the fields of sports, beauty, gut health, and mental resilience. The supplements are produced according to the pure-substance principle, without auxiliary substances and additives.
- Jul 2024Seed—
- Jun 2020Seed$2.2M
- Conventional Debt—
#12
Public · Vienna, Vienna · founded 2006 · 39 employees$193.1Mraised▾
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABP/VABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDA/MAA filing) and pediatric indications (phase I).
- Dec 2018Conventional Debt$25M
- Jul 2018Post IPO$21.3M
- Apr 2015Series B$120M
- Oct 2009PE$22.3M
Funding & investor landscape
Notable founders
How research on Biotechnology is moving in Austria
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 227 Austria-affiliated papers.
- TU Wien30
- BOKU University27
- Medical University of Vienna18
- University of Veterinary Medicine Vienna16
- University of Vienna15
- Gene5
- Messenger RNA4
- Transcription (linguistics)4
- Biogenesis3
- Ribonucleoprotein3
- Agriculture3
- Microbiome3
- Phenotype3
- Resistance (ecology)3
- Bacteria3
- Agriculture7
- Metagenomics6
- Microbiome6
- Food safety4
- Key (lock)3
Where biotechnology is researched across Austria
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.